The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial

Michelle Kam; Julien Caliez; Hilario Nunes; Thomas Gille

doi:10.1183/20734735.0074-2022

The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial

Breathe (Sheff). 2022 Sep;18(3):220074. doi: 10.1183/20734735.0074-2022. Epub 2022 Sep 13.

Authors

Michelle Kam^{1

2}, Julien Caliez^{3

2}, Hilario Nunes^{3

4}, Thomas Gille^{4

5

6}

Affiliations

¹ Dept of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore.
² Both authors contributed equally to this manuscript.
³ Dept of Pulmonology, Reference Center for Rare Pulmonary Diseases, Avicenne University Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis (HUPSSD), Assistance Publique - Hôpitaux de Paris (AP-HP), Bobigny, France.
⁴ Inserm UMR 1272 "Hypoxia & the Lung", UFR Santé, Médecine, Biologie Humaine (SMBH), Université Sorbonne Paris Nord (USPN), Bobigny, France.
⁵ Dept of Physiology and Functional Explorations, Avicenne University Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis (HUPSSD), Assistance Publique - Hôpitaux de Paris (AP-HP), Bobigny, France.
⁶ Dept of Physiology and Functional Explorations, Jean Verdier University Hospital, Hôpitaux Universitaires de Paris Seine-Saint-Denis (HUPSSD), Assistance Publique - Hôpitaux de Paris (AP-HP), Bondy, France.

Abstract

The PANTHER-IPF trial was a turning point in treatment of idiopathic pulmonary fibrosis (#IPF) highlighting the importance of randomised controlled trials in determining treatment strategies, even for rare diseases and/or potentially fatal acute events https://bit.ly/3Oi0KwD.